This compilation of briefs addresses a range of issues the new administration will face in the coming years. “It is our hope that these Baker Institute studies will prove to be useful starting points for the new administration to develop comprehensive, forward-looking solutions," said Baker Institute Director Edward Djerejian.
The United States has a unique opportunity to reduce the spread of disease by engaging the leaders of the G20 countries and targeting neglected diseases. Fellow Peter Hotez explains how.
Little is known about regional variation in cancer treatment and its determinants. In this publication, authors compare rates of adherence to treatment guidelines for elderly patients across Texas and whether local specialist supply is an important determinant of treatment variation.
State "right to try" laws can give terminally ill patients early access to experimental drugs and medical devices — but they arguably make safety and efficacy secondary to speedy access.
This blog post examines four factors of globalization that make Texas a “ground zero” for new infectious tropical diseases and outlines steps the state must take to better mitigate global health threats.
State-based Medicaid programs have begun using All Patient Refined–Diagnosis-Related Groups (APR-DRGs) to determine hospital reimbursement rates. This study examined how well APR-DRGs reflect admission costs for childhood cancer chemotherapy to inform clinicians, hospitals and policymakers in the wake of policy changes.
Current medical research and literature may be overemphasizing the role that hospital volume plays in patient outcomes, according to a study co-authored by health economics fellow Vivian Ho.
Woohyeon Kim, Stephen Wolff, Vivian HoApril 15, 2016
High cancer drug prices reduce access to therapy, cause treatment abandonment and financial bankruptcies, as well as severe emotional and family distress.
This journal article examines the risks patients face in seeking experimental stem cell-based interventions from clinics outside the United States. The authors advocate for new public policies that encourage patients to remain in clinical trials in the U.S.
Kirstin R.W. Matthews, Ana S. IltisNovember 4, 2015
Participants in the 2015 student-led Public Diplomacy and Global Policy Program report their research findings on education, energy, health and gender and equality issues in Doha, Qatar. Edited by Kristian Coates Ulrichsen and Ariana Marnicio.
Kristian Coates Ulrichsen, Ariana MarnicioNovember 2, 2015